Valvular & structural heart disease
Clinical outcomes of transcatheter mitral valve replacement: two-year results of the CHOICE-MI Registry
Authors' conclusion
In this real-world registry of patients with symptomatic MR undergoing TMVR, treatment with TMVR was associated with a durable resolution of MR and significant functional improvement at 2 years. Two-year mortality was 38.1%.
Study context
- Population
- High-risk patients with symptomatic mitral regurgitation undergoing transcatheter mitral valve replacement (TMVR)
- Participants
- 400 patients
- Outcome
- Mortality and predictors of mortality
- Follow-up
- 2 years
Methodological detailsconsecutive patients, 31 international centres
- Consecutive patients
- 31 international centres
Main finding
As reported in the abstract
All-cause mortality
| Group | 30 days | 1 year | 2 years |
|---|---|---|---|
| TMVR | 9.2% | 27.9% | 38.1% |
TMVR
30 days9.2%
1 year27.9%
2 years38.1%
Observational data: associations, not effects.
Further findings
Technical success
- Technical success achieved
- 95.2%
Mitral regurgitation (MR) reduction to ≤1+ · discharge
- MR ≤1+ at discharge, durable at 1 and 2 years
- 95.2%
NYHA functional class · 1 and 2 years
- NYHA class improved significantly at 1 and 2 years
Independent predictors of 2-year mortality
- Chronic obstructive pulmonary disease, reduced GFR and low serum albumin independently predicted 2-year mortality
30-day complications and 2-year mortality
- LV outflow tract obstruction, access site and bleeding complications had the strongest impact on 2-year mortality
Safety
30-day complications and 2-year mortality
- LV outflow tract obstruction, access site and bleeding complications showed the strongest impact on 2-year mortality
Original publication
Clinical outcomes of transcatheter mitral valve replacement: two-year results of the CHOICE-MI Registry. EuroIntervention. Published 21 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →